1Kane JM, Carson WH, Saha AZ, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and scahizoaffective disorder. J Clin payiatry ,2002,63:761-763.
4Stahl SM. dopamine system stabilizers, aripirazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry ,2001,62 ( 11 ) :841-842.
5姜佐宁.现代精神病学(下册)(第2版)[M].北京:科学出版社,2001.1081-1084.
6Noue A,Seto M, Sugita S, et al. differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res, 1998,55:285-292.
7Jordan S,Koprivica V,Chen R,et al. The antipsychotic aripiprazole is a potent ,partial agonist at the human 5-HT(1A) neceptor. Eur J Pharmacol ,2002,441 ( 3 ): 137-140.
8Goodnick PJ,Jerry JM. Aripiprazole:profile on efficacy and safety. Expert Opin Pharmacother,2002,3 ( 12 ): 1773-1781.
